These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 23646979)
1. Advances in the development of hybrid anticancer drugs. Fortin S; Bérubé G Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979 [TBL] [Abstract][Full Text] [Related]
3. An overview of molecular hybrids in drug discovery. Bérubé G Expert Opin Drug Discov; 2016; 11(3):281-305. PubMed ID: 26727036 [TBL] [Abstract][Full Text] [Related]
4. Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents. Tandon VK; Kumar S Expert Opin Ther Pat; 2013 Sep; 23(9):1087-108. PubMed ID: 23651032 [TBL] [Abstract][Full Text] [Related]
5. The potential of combi-molecules with DNA-damaging function as anticancer agents. Sun G; Fan T; Zhao L; Zhou Y; Zhong R Future Med Chem; 2017 Mar; 9(4):403-435. PubMed ID: 28263086 [TBL] [Abstract][Full Text] [Related]
6. Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Noureen N; Rashid H; Kalsoom S Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613 [TBL] [Abstract][Full Text] [Related]
7. Importance of molecular computer modeling in anticancer drug development. Geromichalos GD J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268 [TBL] [Abstract][Full Text] [Related]
8. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
10. Coumarin-containing hybrids and their anticancer activities. Zhang L; Xu Z Eur J Med Chem; 2019 Nov; 181():111587. PubMed ID: 31404864 [TBL] [Abstract][Full Text] [Related]
15. Recent researches in metal supramolecular complexes as anticancer agents. Zhou CH; Zhang YY; Yan CY; Wan K; Gan LL; Shi Y Anticancer Agents Med Chem; 2010 Jun; 10(5):371-95. PubMed ID: 20380632 [TBL] [Abstract][Full Text] [Related]
16. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Xu Z; Zhao SJ; Liu Y Eur J Med Chem; 2019 Dec; 183():111700. PubMed ID: 31546197 [TBL] [Abstract][Full Text] [Related]
17. Hybrid Compounds as Multitarget Directed Anticancer Agents. Kucuksayan E; Ozben T Curr Top Med Chem; 2017; 17(8):907-918. PubMed ID: 27697050 [TBL] [Abstract][Full Text] [Related]
18. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan. Kawabata-Shoda E; Masuda S; Kimura H J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857 [TBL] [Abstract][Full Text] [Related]